Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Prospective evaluation of contrast-enhanced ultrasound of breast BI-RADS 3-5 lesions

E. Janu, L. Krikavova, J. Little, K. Dvorak, D. Brancikova, E. Jandakova, T. Pavlik, P. Kovalcikova, T. Kazda, V. Valek

. 2020 ; 20 (1) : 66. [pub] 20200617

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020453

Grantová podpora
MMCI 00209805 Ministerstvo Zdravotnictví Ceské Republiky - International
MMCI 00209805 Ministerstvo Zdravotnictví Ceské Republiky - International

BACKGROUND: To determine the benefit of contrast-enhanced ultrasound (CEUS) in the assessment of breast lesions. METHODS: A standardized contrast-enhanced ultrasound was performed in 230 breast lesions classified as BI-RADS category 3 to 5. All lesions were subjected to qualitative and quantitative analysis. MVI (MicroVascular Imaging) technique was used to derive qualitative analysis parameters; blood perfusion of the lesions was assessed (perfusion homogeneity, type of vascularization, enhancement degree). Quantitative analysis was conducted to estimate perfusion changes in the lesions within drawn regions of interest (ROI); parameters TTP (time to peak), PI (peak intensity), WIS (wash in slope), AUC (area under curve) were obtained from time intensity (TI) curves. Acquired data were statistically analyzed to assess the ability of each parameter to differentiate between malignant and benign lesions. The combination of parameters was also evaluated for the possibility of increasing the overall diagnostic accuracy. Biological nature of the lesions was verified by a pathologist. Benign lesions without histopathological verification (BI-RADS 3) were followed up for at least 24 months. RESULTS: Out of 230 lesions, 146 (64%) were benign, 67 (29%) were malignant, 17 (7%) lesions were eliminated. Malignant tumors showed statistically significantly lower TTP parameters (sensitivity 77.6%, specificity 52.7%) and higher WIS values (sensitivity 74.6%, specificity 66.4%) than benign tumors. Enhancement degree also proved to be statistically well discriminating as 55.2% of malignant lesions had a rich vascularity (sensitivity 89.6% and specificity 48.6%). The combination of quantitative analysis parameters (TTP, WIS) with enhancement degree did not result in higher accuracy in distinguishing between malignant and benign breast lesions. CONCLUSIONS: We have demonstrated that contrast-enhanced breast ultrasound has the potential to distinguish between malignant and benign lesions. In particular, this method could help to differentiate lesions BI-RADS category 3 and 4 and thus reduce the number of core-cut biopsies performed in benign lesions. Qualitative analysis, despite its subjective element, appeared to be more beneficial. A combination of quantitative and qualitative analysis did not increase the predictive capability of CEUS.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020453
003      
CZ-PrNML
005      
20210830102129.0
007      
ta
008      
210728s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12880-020-00467-2 $2 doi
035    __
$a (PubMed)32552678
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Janu, Eva $u The Clinic of Radiology and Nuclear Medicine, The University Hospital Brno, Brno, Czech Republic $u The Clinic of Radiology and Nuclear Medicine, Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a Prospective evaluation of contrast-enhanced ultrasound of breast BI-RADS 3-5 lesions / $c E. Janu, L. Krikavova, J. Little, K. Dvorak, D. Brancikova, E. Jandakova, T. Pavlik, P. Kovalcikova, T. Kazda, V. Valek
520    9_
$a BACKGROUND: To determine the benefit of contrast-enhanced ultrasound (CEUS) in the assessment of breast lesions. METHODS: A standardized contrast-enhanced ultrasound was performed in 230 breast lesions classified as BI-RADS category 3 to 5. All lesions were subjected to qualitative and quantitative analysis. MVI (MicroVascular Imaging) technique was used to derive qualitative analysis parameters; blood perfusion of the lesions was assessed (perfusion homogeneity, type of vascularization, enhancement degree). Quantitative analysis was conducted to estimate perfusion changes in the lesions within drawn regions of interest (ROI); parameters TTP (time to peak), PI (peak intensity), WIS (wash in slope), AUC (area under curve) were obtained from time intensity (TI) curves. Acquired data were statistically analyzed to assess the ability of each parameter to differentiate between malignant and benign lesions. The combination of parameters was also evaluated for the possibility of increasing the overall diagnostic accuracy. Biological nature of the lesions was verified by a pathologist. Benign lesions without histopathological verification (BI-RADS 3) were followed up for at least 24 months. RESULTS: Out of 230 lesions, 146 (64%) were benign, 67 (29%) were malignant, 17 (7%) lesions were eliminated. Malignant tumors showed statistically significantly lower TTP parameters (sensitivity 77.6%, specificity 52.7%) and higher WIS values (sensitivity 74.6%, specificity 66.4%) than benign tumors. Enhancement degree also proved to be statistically well discriminating as 55.2% of malignant lesions had a rich vascularity (sensitivity 89.6% and specificity 48.6%). The combination of quantitative analysis parameters (TTP, WIS) with enhancement degree did not result in higher accuracy in distinguishing between malignant and benign breast lesions. CONCLUSIONS: We have demonstrated that contrast-enhanced breast ultrasound has the potential to distinguish between malignant and benign lesions. In particular, this method could help to differentiate lesions BI-RADS category 3 and 4 and thus reduce the number of core-cut biopsies performed in benign lesions. Qualitative analysis, despite its subjective element, appeared to be more beneficial. A combination of quantitative and qualitative analysis did not increase the predictive capability of CEUS.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a prsy $x diagnostické zobrazování $x patologie $7 D001940
650    _2
$a nádory prsu $x diagnostické zobrazování $x patologie $7 D001943
650    _2
$a kontrastní látky $7 D003287
650    _2
$a diferenciální diagnóza $7 D003937
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a prospektivní studie $7 D011446
650    _2
$a senzitivita a specificita $7 D012680
650    _2
$a ultrasonografie prsů $x metody $7 D016217
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Krikavova, Lucie $u The Clinic of Radiology and Nuclear Medicine, The University Hospital Brno, Brno, Czech Republic
700    1_
$a Little, Jirina $u The Clinic of Radiology and Nuclear Medicine, The University Hospital Brno, Brno, Czech Republic
700    1_
$a Dvorak, Karel $u The Clinic of Radiology and Nuclear Medicine, The University Hospital Brno, Brno, Czech Republic
700    1_
$a Brancikova, Dagmar $u The Clinic of Internal Medicine - Haematology and Oncology, The University Hospital Brno, Brno, Czech Republic
700    1_
$a Jandakova, Eva $u The Institute of Pathology, The University Hospital Brno, Brno, Czech Republic
700    1_
$a Pavlik, Tomas $u The Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic
700    1_
$a Kovalcikova, Petra $u The Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic
700    1_
$a Kazda, Tomas $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 65653, Brno, Czech Republic. tomas.kazda@mou.cz $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. tomas.kazda@mou.cz
700    1_
$a Valek, Vlastimil $u The Clinic of Radiology and Nuclear Medicine, The University Hospital Brno, Brno, Czech Republic
773    0_
$w MED00006823 $t BMC medical imaging $x 1471-2342 $g Roč. 20, č. 1 (2020), s. 66
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32552678 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830102129 $b ABA008
999    __
$a ok $b bmc $g 1691094 $s 1140899
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 20 $c 1 $d 66 $e 20200617 $i 1471-2342 $m BMC medical imaging $n BMC Med Imaging $x MED00006823
GRA    __
$a MMCI 00209805 $p Ministerstvo Zdravotnictví Ceské Republiky $2 International
GRA    __
$a MMCI 00209805 $p Ministerstvo Zdravotnictví Ceské Republiky $2 International
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace